Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07584434 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of VX-433
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 118
- Enrollment target
NCT07584434: Recruiting Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT07584434 is a Phase 1 study that is actively recruiting participants, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 118 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07584434, a Phase 1 study, is actively recruiting participants, sponsored by Vertex Pharmaceuticals Incorporated.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG Bupropion
- DRUG VX-433
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2027-03-05 |
| Phase | Phase 1 |
What NCT07584434 shows while recruiting
NCT07584434 is an interventional study that assigns participants to a tested intervention. The registered 118 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (97% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07584434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07584434 about?
NCT07584434 is a clinical study titled "A Phase 1, First-in-human Study of VX-433". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
What is the current status of trial NCT07584434?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 118 participants. The study started on 2026-05-21. Estimated completion is 2027-03-05.
What interventions are being tested in trial NCT07584434?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), Bupropion (DRUG), VX-433 (DRUG).
Who is sponsoring clinical trial NCT07584434?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07584434's enrollment target sits among peer trials
118 499th of 2000 higher than 1,502 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03821623 · 118 participants · Phase 2
Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults
- NCT04040959 · 118 participants · Phase 2
Nicotinamide Riboside Supplementation for Treating Arterial Stiffness and Elevated Systolic Blood Pressure in Patients With Moderate to Severe CKD
- NCT04696029 · 118 participants · Phase 2
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma
- NCT05223192 · 118 participants · NA
The Effects of Entrainment on Respiratory Stability and Cerebral Oxygenation in Preterm Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI